Azoximer bromide (Polyoxidonium) 12 mg – [10 tablets]

Azoximera bromide has a complex action: immunomodulatory, detoxifying, antioxidant, moderate anti-inflammatory.

The basis of the mechanism of immunomodulatory action of Azoximer bromide is a direct impact on phagocytic cells and natural killer cells, as well as stimulation of antibody formation, synthesis of interferon-alpha and interferon-gamma.

The detoxifying and antioxidant properties of Azoximer bromide are largely determined by the structure and high molecular weight nature of the drug. Azoximera bromide increases the body’s resistance to local and generalized infections of bacterial, fungal and viral etiology. Restores immunity in secondary immunodeficiency conditions caused by various infections, injuries, complications after surgery, burns, autoimmune diseases, malignant tumors, chemotherapy drugs, cytostatics, steroid hormones. The use of Polioxidonium® against secondary immunodeficiency states can improve and shorten the duration of treatment, significantly reduce the use of antibiotics, bronchodilators, glucocorticosteroids and extend the period of remission.

Inclusion of Polioxidonium® in the treatment of cancer patients reduces intoxication during chemotherapy and radiation therapy and in most cases allows the standard therapy without changing the regimen due to the development of infectious complications and side effects (myelosuppression, vomiting, diarrhea, cystitis, colitis and others).

A characteristic feature of Azoximer bromide when used topically (intranasally, sublingually) is the ability to activate the body’s early defense factors against infection: the drug

stimulates bactericidal properties of neutrophils, macrophages, enhances their ability to absorb bacteria, increases the bactericidal properties of saliva and mucosal secretion of the upper respiratory tract.

Azoximera bromide blocks soluble toxic substances and microparticles, has the ability to remove from the body toxins, salts of heavy metals, inhibits lipid peroxidation by both intercepting free radicals and through the elimination of catalytically active Fe2+ ions. Azoximera bromide reduces the inflammatory response by normalizing the synthesis of pro- and anti-inflammatory cytokines.

Azoximera bromide is well tolerated, has no mitogenic, polyclonal activity, antigenic properties, has no allergic, mutagenic, embryotoxic, teratogenic and carcinogenic effect. Azoximera bromide

is odorless and tasteless, has no local irritant effect when applied to the mucous membranes of the nose and oropharynx.

It is used in adults and children from 6 months for treatment and prophylaxis of infectious and inflammatory diseases (of viral, bacterial and fungal etiology), with acute and remission phases.

For the treatment of adults (in combination therapy):

– Chronic recurrent inflammatory and infectious diseases of various localizations, bacterial, viral and fungal etiology in acute remission stage;

– Acute viral, bacterial infections of ENT-organs, upper and lower respiratory tract, gynecological and urological diseases;

– acute and chronic allergic diseases (including pollinosis, bronchial asthma, atopic dermatitis), complicated by bacterial, viral and fungal infections;

– malignant tumors during and after chemotherapy and radiation therapy to reduce the immunosuppressive, nephro- and hepatotoxic effects of drugs;

– generalized forms of surgical infections; for activation of regenerative processes (fractures, burns, trophic ulcers);

– rheumatoid arthritis, complicated by bacterial, viral and fungal infections, against the background of long-term immunosuppressants;

– pulmonary tuberculosis.

For the treatment of children over 6 months (in the complex therapy):

– Acute and exacerbation of chronic inflammatory diseases of any localization (including ENT-organs – sinusitis, rhinitis, adenoiditis, pharyngeal tonsil hypertrophy, ARVI), caused by pathogens of bacterial, viral, fungal infections;

– acute allergic and toxic-allergic conditions complicated by bacterial, viral and fungal infections;

– Bronchial asthma complicated by chronic respiratory tract infections;

– Atopic dermatitis complicated by purulent infection;

– intestinal dysbacteriosis (in combination with specific therapy).

For the prevention (monotherapy) in children over 6 months and adults:

– Influenza and acute respiratory infections;

– postoperative infectious complications.